ArticleMedicine2026
Protection motivation theory-based management after surgery for osteoporotic vertebral fractures: Modulating inflammatory factors and pain mediators, and ameliorating hypercoagulability and bone metabolism.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The purpose of this research was to investigate how the protection motivation theory (PMT)-based management model influences inflammatory factors, pain mediators, coagulation function, and bone metabolism in postsurgical osteoporotic vertebral fracture (OVF) patients. Between February 2024 and March 2025, OVF patients undergoing surgery at our center were recruited for this investigation. Ultimately, 74 patients were assigned to the PMT group, compared with 71 who were designated as controls. For each participant, venous blood sampling under fasting conditions was performed preoperatively and on postoperative day 5. We then measured a comprehensive set of parameters using dedicated techniques: inflammatory factors (interleukin-1 beta [IL-1β], interleukin-6, interleukin-10 [IL-10], tumor necrosis factor-α, high-sensitivity C-reactive protein [hs-CRP]) and bone metabolism markers (C-terminal telopeptide of type I collagen [CTX], bone Gla protein [BGP], osteocalcin [OC]) via enzyme-linked immunosorbent assay, pain mediators (substance P [SP], prostaglandin E2 [PGE2]) via radioimmunoassay, oxidative stress markers (malondialdehyde [MDA], superoxide dismutase) via the thiobarbituric acid method, and coagulation parameters (D-dimer [D-D], fibrinogen [FIB], P-selectin, platelet) via an automatic coagulation analyzer. The resulting data were subjected to both intragroup and intergroup comparative analyses. In addition, the adverse reactions during the perioperative period were counted, and the Japanese Orthopaedic Association (JOA) scores and Barthel index (BI) questionnaires were conducted before and 1 month after the operation to evaluate the rehabilitation quality of the patients. Surgical intervention resulted in an increase in IL-1β, interleukin-6, tumor necrosis factor-α, hs-CRP, SP, PGE2, MDA, D-D, FIB, P-selectin, and CTX, as well as a decrease in IL-10, superoxide dismutase, BGP, and OC in both cohorts (P < .05). According to intergroup analyses, the PMT group exhibited lower IL-1β, hs-CRP, SP, PGE2, MDA, D-D, FIB, and CTX, along with higher IL-10, platelet, BGP, and OC, than controls (P < .05). The incidence of perioperative deep vein thrombosis in the PMT group was lower than that in the control group (P < .05). Although the JOA and BI of the 2 groups were higher than those before operation, the JOA and BI of the PMT group were higher than those of the control group at 1 month after operation (P < .05). Early postoperative adoption of PMT-based management following OVF surgery contributes to significant clinical improvements by suppressing systemic inflammation, limiting pain mediator synthesis, ameliorating hypercoagulability, and normalizing disrupted bone metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.